VTRSViatris
Is the business good?
Margins compressing. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has narrowed over the past few years, profitability per dollar of sales is eroding.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is VTRS?
Viatris earns −0.26% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 9.3 points below what the capital costs: growth destroys value
- Operating margin
- −0.59%
Operating margin · Drug Manufacturers - Specialty & Generic median 9.5% · 12 months to Q2 2026
- Share count, year on year
- −0.83%
Share count, year on year · flat: no meaningful dilution
- R&D as % of revenue
- 6.9%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −1.8% |
| FY2021 | −0.19% |
| FY2022 | 9.9% |
| FY2023 | 5.0% |
| FY2024 | 0.07% |
| FY2025 | −19% |
Details›
- Gross margin12 months to Q2 2026
- 35%
- Operating margin12 months to Q2 2026
- −0.59%
- Net margin12 months to Q2 2026
- −2.8%
- Free cash flow margin
- 13%
- R&D as % of revenue
- 6.9%
- Revenue, trailing twelve months
- $14.7B
- Free cash flow, trailing twelve months
- $1.95B
- Net income, trailing twelve months
- −$411M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −0.26%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from VTRS and who it buys from, as the companies report it.
- CORCencora11%
Share of revenue · FY2025 10-K
- Top three customers25%
Combined share of revenue · FY2025 10-K
None disclosed.
A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; VTRS’s own figures are from its FY2025 10-K. Smaller customers and suppliers go unreported.
Drug Manufacturers, Specialty & Generic
The closest names by size in the same industry